These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8400352)

  • 21. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.
    Sark MW; Timmer-Bosscha H; Meijer C; Uges DR; Sluiter WJ; Peters WH; Mulder NH; de Vries EG
    Br J Cancer; 1995 Apr; 71(4):684-90. PubMed ID: 7710929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
    Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
    Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin.
    Nakagawa K; Yokota J; Wada M; Sasaki Y; Fujiwara Y; Sakai M; Muramatsu M; Terasaki T; Tsunokawa Y; Terada M
    Jpn J Cancer Res; 1988 Mar; 79(3):301-4. PubMed ID: 2836347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
    Shellard SA; Hosking LK; Hill BT
    Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
    Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II).
    Bedford P; Walker MC; Sharma HL; Perera A; McAuliffe CA; Masters JR; Hill BT
    Chem Biol Interact; 1987 Jan; 61(1):1-15. PubMed ID: 3815585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.
    Oldenburg J; Begg AC; van Vugt MJ; Ruevekamp M; Schornagel JH; Pinedo HM; Los G
    Cancer Res; 1994 Jan; 54(2):487-93. PubMed ID: 8275486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin.
    Twentyman PR; Wright KA; Rhodes T
    Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):217-20. PubMed ID: 1846846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells.
    Pan SS; Yu F; Hipsher C
    Mol Pharmacol; 1993 Jun; 43(6):870-7. PubMed ID: 8316219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line.
    Singh SV; Xu BH; Jani JP; Emerson EO; Backes MG; Rihn C; Scalamogna D; Stemmler N; Specht S; Blanock K
    Int J Cancer; 1995 May; 61(3):431-6. PubMed ID: 7729958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
    O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
    Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
    Johnson SW; Laub PB; Beesley JS; Ozols RF; Hamilton TC
    Cancer Res; 1997 Mar; 57(5):850-6. PubMed ID: 9041185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.
    Blommaert FA; Floot BG; van Dijk-Knijnenburg HC; Berends F; Baan RA; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
    Chem Biol Interact; 1998 Jan; 108(3):209-25. PubMed ID: 9528691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines.
    Parsons PG; Lean J; Kable EP; Favier D; Khoo SK; Hurst T; Holmes RS; Bellet AJ
    Biochem Pharmacol; 1990 Dec; 40(12):2641-9. PubMed ID: 2260988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of drug response in a cisplatin-resistant human lung cancer cell line.
    Fujiwara Y; Sugimoto Y; Kasahara K; Bungo M; Yamakido M; Tew KD; Saijo N
    Jpn J Cancer Res; 1990 May; 81(5):527-35. PubMed ID: 2116401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
    Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
    Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
    Hettinga JV; Lemstra W; Meijer C; Dam WA; Uges DR; Konings AW; De Vries EG; Kampinga HH
    Br J Cancer; 1997; 75(12):1735-43. PubMed ID: 9192975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.